Investor Relations

Upcoming Events

2023 15th World Stroke Congress

14th Annual Craig-Hallum Alpha Select Conference

International Stroke Conference 2024

Most Recent Business Quarterly Update

Second Quarter 2023 Financial Results Update

Company Overview

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke and cardio-renal disease.

Investor Contact Information

Company

DiaMedica Therapeutics, Inc.
301 Carlson Parkway
Suite 210
Minneapolis, MN 55305

Investor Relations

DiaMedica Therapeutics Inc.
Scott Kellen
Chief Financial Officer
T: (763) 496-5192
F: (763) 710-4456
skellen@diamedica.com